Davide Capodanno/LinkedIn
Jan 11, 2026, 03:54
DAPT De-escalation After PCI․ Where Do We Stand Today?
Davide Capodanno, Full Professor of Cardiology at the University of Catania, shared on X:
“ DAPT after PCI remains essential, but balancing ischemic protection and bleeding risk is challenging. Over the past decade, trials have supported DAPT de-escalation—via dose reduction, drug withdrawal, or switching agents—to reduce bleeding without compromising ischemic outcomes in selected patients. Evidence for escalation is more limited. We wrote this review to summarize current data and ongoing studies. ”
Title: Dual Antiplatelet Therapy Escalation and De-escalation
Authors: Antonio Greco, Giacinto Di Leo, Simone Finocchiaro, Antonino Imbesi, Davide Capodanno
Read full article here.

Stay updated with Hemostasis Today.
-
Jul 12, 2026, 07:13Ekaterina Balaian: Finding Healing Through Art at ISTH 2026
-
Jul 12, 2026, 06:59Maaike Sybil Jongen: Flow Cytometry for Platelet Phenotyping at ISTH 2026
-
Jul 12, 2026, 06:45Brian O Mahony: Advancing Concizumab Therapy for Hemophilia With Inhibitors at ISTH 2026
-
Jul 12, 2026, 06:42PERT-Guided Patient Selection for Advanced Pulmonary Embolism Therapies
-
Jul 12, 2026, 06:12Precision in Antithrombotic Therapy at ISTH 2026 – The Lancet Haematology
-
Jul 11, 2026, 23:36Emmanuel J Favaloro: A Fresh Perspective on the Manual Tilt Tube Method for PT and INR Determination
-
Jul 11, 2026, 21:47Michelle Meyer: Working Together to Advance Stroke Prevention in Atrial Fibrillation
-
Jul 11, 2026, 21:44Timos Papagatsias: From Promising Concepts to Clinical Differentiation at ISTH 2026
-
Jul 11, 2026, 21:43Sharing New Research in Hemophilia at ISTH 2026 – Novo Nordisk Medical US